Investors are always looking for stocks that are poised to beat at earnings season LifePoint Health, Inc. may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because LifePoint Health is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for LPNT in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $1.14 per share for LPNT, compared to a broader Zacks Consensus Estimate of $1.10 per share. This suggests that analysts have very recently bumped up their estimates for LPNT, giving the stock a Zacks Earnings ESP of +4.25% heading into earnings season.
LifePoint Health, Inc. Price and EPS Surprise
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that LPNT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for LifePoint Health, and that a beat might be in the cards for the upcoming report.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Image: Bigstock
Should You Buy LifePoint Health (LPNT) Ahead of Earnings?
Investors are always looking for stocks that are poised to beat at earnings season LifePoint Health, Inc. may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because LifePoint Health is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for LPNT in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $1.14 per share for LPNT, compared to a broader Zacks Consensus Estimate of $1.10 per share. This suggests that analysts have very recently bumped up their estimates for LPNT, giving the stock a Zacks Earnings ESP of +4.25% heading into earnings season.
LifePoint Health, Inc. Price and EPS Surprise
LifePoint Health, Inc. Price and EPS Surprise | LifePoint Health, Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that LPNT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for LifePoint Health, and that a beat might be in the cards for the upcoming report.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>